First Canadian experience with donation after cardiac death simultaneous pancreas and kidney transplants

Patrick T. Anderson, MD
Shahid Aquil, MD
Kelly McLean, MD
Vivian C. McAlister, MB
Alp Sener, MD
Patrick P. Luke, MD

Accepted Mar. 1, 2017; Early-released Aug. 1, 2017; subject to revision

Correspondence to:
P. Luke
Department of Surgery
Division of Urology
Western University Hospital
339 Windermere Rd
London ON N6A 6A6
patrick.luke@lhsc.on.ca

DOI: 10.1503/cjs.011315
Patients with diabetes mellitus and end-stage renal disease (ESRD) have high rates of morbidity and mortality.\textsuperscript{1–3} The simultaneous pancreas and kidney transplant (SPK) has been shown to improve quality of life and significantly impact survival of patients with ESRD and diabetes.\textsuperscript{4} However, the global demand for SPK transplant continues to outpace the availability of suitable donor grafts, which has led to transplant wait lists.\textsuperscript{5–8} To overcome this barrier, expansion of donor criteria is being studied to address the imbalance in organ supply and demand in North America.\textsuperscript{9,10} One such provision in the expansion of donor criteria has been the use of donation after cardiac death (DCD) donor grafts in patients requiring an SPK transplant. Compared with the standard neurologic determination of death (NDD) donor grafts, pancreas grafts from DCD donors have traditionally been believed to be of inferior quality owing to the damage to these grafts during the period of warm ischemia between cessation of donor cardiopulmonary circulation and administration of cold perfusion during organ procurement.\textsuperscript{11,12} The theoretical risks about graft quality have limited the use of DCD grafts in SPK transplantation. Between 2006 and 2012, only 320 pancreas grafts from DCD donors were transplanted in the United States compared with 20,448 pancreas grafts from NDD donors.\textsuperscript{13}

As a measure of quality assurance, we present a study of, to our knowledge, the first Canadian experience with DCD SPK transplants. Specifically, we compared the rates of postoperative complications, laboratory parameters of graft function, and long-term patient and graft survival between SPK transplants from DCD and NDD donors.

**Methods**

**Patient selection**

All patients who underwent SPK transplantation using DCD donor grafts between October 2008 and July 2016 at our single, large tertiary care institution were included in the study. Patient data were collected for analysis from the time of transplant until July 2016.

**Study design**

We performed a retrospective cohort study comparing all SPK transplants from DCD donors to those from all NDD donors. The demographic data, quantitative laboratory tests of short and long-term graft function, surgical complications, and patient and graft survivals were compared between the groups.

**Organ procurement**

After confirming the donors’ histories were free of diabetes or pancreatitis, the decision to accept the grafts was mainly based on donor age, history of diabetes, body mass index (BMI) and quality of the organs during procurement surgery and after flushing. The pancreas was not used if there was evidence of significant trauma, severe fibrosis, or pancreatitis. Initial warm ischemia time was limited to 30 minutes, but with very minor impact on graft function and pancreas graft thrombosis, we extended this threshold to 60 minutes. Initially only younger patients were considered candidates for DCD grafts, but based on our experience of acceptable graft function with DCD grafts, all patients on our waiting list are considered for DCD transplant.

In all cases the pancreas and kidneys were flushed with Belzer University of Wisconsin solution. Kidneys were stored in either cold static solution using University of Wisconsin solution, or in a pulsatile cold preservation machine (LifePort, Organ Recovery Systems) using KPS solution (Organ Recovery Systems).

**Transplant procedure**

Standard kidney transplants were performed in the left iliac fossa. Pancreas transplants were completed in the right iliac fossa using systemic and enteric drainage.
**Immune suppression**

Immunosuppression was induced with 250 mg of methylprednisolone, which was given on call to the operating room. Thymoglobulin (1.5 mg/kg) was started before skin incision and administered over 6–8 hours. Myfortic (720 mg orally twice daily) was started on postoperative day 0. Tacrolimus was initiated on day 3 (trough level 5–8). Methylprednisolone was then started at 1 mg/kg with daily tapering by 10 mg/d until a minimum of 5 mg/d was reached. Steroids were withdrawn only if a protocol kidney biopsy at 3 months was free of rejection.

Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days after SPK transplant.\(^{14}\)

**Statistical analysis**

Statistical analysis was carried out using Graphpad Prism 6 (GraphPad Software, Inc.). We used the Mann–Whitney test to compare means between groups and the \(\chi^2\) test to compare categorical variables. Survival curves for patient and graft survival were generated using the Kaplan–Meier method and compared using the log-rank test. All statistical tests were 2-sided, and statistical significance was accepted at the 95% confidence interval with \(p < 0.05\). Data are presented as means with standard deviations.

**RESULTS**

Thirteen DCD and 68 NDD SPK transplants were performed at our institution between October 2008 and July 2016 (Fig. 1). Median follow-up was 2.2 (range 0.1–6.7) years and 2.7 (range 0.3–6.3) years for DCD and NDD groups, respectively (Table 1).

**Donor characteristics**

Characteristics of the SPK donors and graft ischemia times are shown in Table 1. Donor characteristics were similar between the DCD and NDD groups with respect to age, sex, BMI, terminal creatinine and kidney cold ischemia time (CIT). The mean pancreas CIT was significantly different between the DCD and NDD groups (10.0 h v. 7.1 h, \(p = 0.049\)). The mean warm ischemia time of kidney and pancreas grafts procured from DCD donors was 0.5 (range 0.4–0.7) hours.

**Recipient characteristics**

Recipient characteristics were similar between the DCD and NDD groups with respect to age, BMI, sex, percent panel reactive antibodies (PRA%), and presence of donor-specific antibodies. There was no history of prior transplants in either of the groups (Table 1).

**Postoperative complications**

Complications are outlined in Table 2. We found no difference in the mean number of units of packed red blood cells transfused to patients between the DCD and NDD transplant groups. There was a significantly higher rate of renal delayed graft function (DGF) after transplant in the DCD group than in the NDD group. In total 38% of patients in the DCD group experienced DGF compared with 10% in the NDD group (\(p = 0.027\)). The mean

---

**Table 1. Donor and recipient demographics of simultaneous pancreas-kidney transplants from DCD and NDD donors**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Group; mean ± SD*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Donors</strong></td>
<td></td>
</tr>
<tr>
<td>Age, yr</td>
<td>DCD (n = 13)</td>
</tr>
<tr>
<td>BMI</td>
<td>24.3 ± 2.0</td>
</tr>
<tr>
<td>Sex, male:female</td>
<td>8:5</td>
</tr>
<tr>
<td>Terminal creatinine</td>
<td>83.9 ± 11.9</td>
</tr>
<tr>
<td>Kidney CIT, hr</td>
<td>8.4 ± 2.6</td>
</tr>
<tr>
<td>Pancreas CIT, hr</td>
<td>10.0 ± 2.7</td>
</tr>
<tr>
<td>WIT, hr</td>
<td>0.5 ± 0.1</td>
</tr>
<tr>
<td>WIT range, hr</td>
<td>0.4 – 0.7</td>
</tr>
<tr>
<td><strong>Recipients</strong></td>
<td></td>
</tr>
<tr>
<td>Age, yr</td>
<td>DCD (n = 13)</td>
</tr>
<tr>
<td>BMI</td>
<td>24.4 ± 0.7</td>
</tr>
<tr>
<td>Sex, male:female</td>
<td>7:6</td>
</tr>
<tr>
<td>PRA%</td>
<td>15.7 ± 7.7</td>
</tr>
<tr>
<td>Donor-specific antibodies, no. (%)</td>
<td>2 (15)</td>
</tr>
<tr>
<td>Follow-up, median (range), yr</td>
<td>DCD (n = 13)</td>
</tr>
<tr>
<td>BMI = body mass index; CIT = cold ischemia time; DCD = donation after cardiac death; NDD = neurologic determination of death; PRA = panel reactive antibodies; SD = standard deviation; WIT = warm ischemia time.</td>
<td></td>
</tr>
</tbody>
</table>
| *Unless indicated otherwise.
The number of hemodialysis sessions required by patients in either group who experienced DGF was not found to be statistically different. There were also 7 cases of pancreas graft thrombosis requiring repeat laparotomy and graft removal in the NDD group. No cases of pancreas graft thrombosis were observed in the DCD group; however, this difference was not found to be significant ($p = 0.50$).

**Immunosuppression**

Table 3 lists the immunosuppression doses received by both the DCD and NDD groups. The mean total thymoglobulin doses and the number of patients who could be tapered off methylprednisone were not found to be statistically different between the groups.

**Serum biochemistry**

We compared the serum biochemistry of patients in the DCD and NDD groups up to 4 years after SPK transplant (Fig. 2). The mean estimated glomerular filtration rate (eGFR) was significantly higher on postoperative days 7 and 14 in the NDD group than in the DCD group. However, from postoperative day 30 to 4 years after transplant, there was no significant difference in mean eGFR.

**Table 2. Postoperative complications of simultaneous pancreas and kidney transplants from DCD and NDD donors**

<table>
<thead>
<tr>
<th>Complication</th>
<th>Group; mean ± SD*</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Units of RBCs, mean ± SE</td>
<td>DCD (n = 13)</td>
<td>NDD (n = 68)</td>
</tr>
<tr>
<td></td>
<td>4.2 ± 1.2</td>
<td>3.4 ± 0.5</td>
</tr>
<tr>
<td>Kidney DGF, %</td>
<td>38</td>
<td>10</td>
</tr>
<tr>
<td>No. of HD sessions in DGF</td>
<td>2.6 ± 0.68</td>
<td>2.6 ± 0.93</td>
</tr>
<tr>
<td>No. of pancreas graft thrombosis and relaparotomy</td>
<td>0</td>
<td>7</td>
</tr>
</tbody>
</table>

**Table 3. Immunosuppression of simultaneous pancreas and kidney transplants**

<table>
<thead>
<tr>
<th>Immunosuppression</th>
<th>Group; mean ± SD or no. (%)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total thymoglobin dose, mg/kg</td>
<td>DCD (n = 13)</td>
<td>NDD (n = 68)</td>
</tr>
<tr>
<td></td>
<td>6.2 ± 0.6</td>
<td>5.9 ± 0.3</td>
</tr>
<tr>
<td>Tapered off methylprednisone</td>
<td>3 (23)</td>
<td>16 (33)</td>
</tr>
</tbody>
</table>

**Fig. 2. Serum biochemistry after simultaneous pancreas and kidney transplant from donation after cardiac death (DCD) and neurologic determination of death (NDD) donors.** *Statistically significant differences. eGFR = estimated glomerular filtration rate.
between the groups. There were no significant differences in mean serum amylase, lipase or HbA1c up to 4 years after transplant between the groups.

**Patient and graft survivals**

Patient and graft survival were followed up to 6 years after SPK transplant (Fig. 3). No significant differences in patient survival were found between the NDD and DCD groups. There was no significant difference in kidney graft survival between the NDD and DCD groups; however, 1 patient in the NDD group underwent severe acute rejection at 2 years after transplant, resulting in the loss of renal graft function. There were 7 events of acute pancreas graft thrombosis requiring relaparotomy and pancreatectomy in the NDD group. There were no pancreas thrombosis events in the DCD group, and no patient from the DCD group required insulin at any point after transplant. Overall, there was no significant difference in pancreas graft survival between the NDD and DCD groups.

**Discussion**

Our study represents, to our knowledge, the first account from a Canadian institution with regards to the use of grafts from DCD donors in SPK transplants. In select patients with type 1 diabetes and end-stage renal disease, SPK transplant has become an excellent treatment option. Traditionally, grafts are derived from NDD donors owing to concerns of increased graft damage during the low perfusion state experienced with DCD grafts. However, the increasing discrepancy between the demand for grafts and their relative scarcity has led to the increased use of DCD donor grafts in SPK transplants worldwide, and in October 2008 we performed the first DCD SPK transplant in Canada. With the novel use of DCD donor grafts, it was of vital importance to assess whether outcomes of DCD SPK transplants were comparable to those of transplants making use of NDD grafts as a measure of quality.

Following SPK transplant, there was a significantly higher rate of DGF in the DCD group than the NDD group (Table 1). This higher rate of DGF was associated

---

Fig. 3. Kaplan–Meier survival analysis of (A) patient survival, (B) kidney allograft survival and (C) pancreas allograft survival up to 6 years after simultaneous pancreas and kidney transplant from donation after cardiac death (DCD) and neurologic determination of death (NDD) donors. No significant differences were seen between groups for patient, kidney or pancreas graft survival.
with a lower eGFR in the DCD than the NDD group up to 14 days after transplant (Fig. 2A). However, by 30 days, the mean eGFR of the DCD group was comparable to that of the NDD group. Both renal function and survival were similar between the DCD and NDD groups up to 4 years after transplant (Fig. 3B). These results support earlier work by D’Alessandro and colleagues,15 who found similar patterns when comparing DCD to NDD SPK transplants.

Although no differences were seen with regards to long-term pancreas survival, 7 patients in the NDD group had graft thrombosis and failure. These events primarily occurred within the first 48 hours after transplant. An explanation for the difference in graft thrombosis may be associated with institution changes to the postoperative management of patients receiving SPK transplants. Beginning in July 2009, all patients receiving SPK transplants were placed on a low-dose intravenous heparin infusion in the immediate postoperative period in order to prevent pancreas graft thrombosis. It is important to note that none of the 7 patients with a pancreas graft thrombosis received a heparin infusion as part of this protocol, and following this change, no events of pancreas graft thrombosis occurred, regardless of donor status.

**Limitations**

The main limitation of our study is the relatively small number of DCD SPK transplants available for our analysis. In addition, donors were relatively young in both groups, and warm ischemic time (WIT) was relatively low in the DCD group. When our institution initially began performing DCD SPK transplants, 30 minutes of WIT was considered the upper threshold owing to concerns of adverse outcomes on graft survival and function. However, our experience allowed us to increase our threshold to 60 minutes of WIT owing to relatively low rates of DGF and pancreas graft thrombosis. The upper limits of WIT for pancreas transplants is not known, but our findings of excellent immediate and long-term pancreatic graft function and absence of thrombosis and pancreatitis (amylase/lipase rise) supports assessment of a longer WIT in the future.

Fernandez and colleagues16 were the first to report on the long-term outcomes of DCD grafts in SPK transplants. Their study included 37 DCD SPK transplants and supported their use, finding them to be equivalent to NDD grafts in the long term. Our study from a single Canadian tertiary care centre has been able to show similar long-term outcomes and strengthens the current evidence for use of DCD grafts in SPK transplants.

**Conclusion**

To our knowledge, our study is the first in Canada to support the use of DCD grafts in SPK transplants. We have shown that outcomes of SPK grafts from DCD and NDD donors are comparable in long-term follow-up. As the demand for organs continues to outpace their availability, we have initial evidence that supports the expansion of donor criteria to include DCD grafts in SPK transplantation.

**Affiliations:** From the Department of Surgery, Division of Urology, The Ottawa Hospital, University of Ottawa, Ottawa, Ont. (Anderson); the Western University Schulich School of Medicine and Dentistry, London, Ont. (McAlister, Sener, Luke); the Department of Surgery, Western University, London, Ont. (Aquil, McLean, McAlister, Sener, Luke); and the Multi-Organ Transplant Program, London Health Sciences Centre, London, Ont. (Aquil, McLean, McAlister, Sener, Luke).

**Competing interests:** None declared.

**Contributors:** V. McAlister and P. Luke designed the study. P. Anderson, S. Aquil and K. McLean acquired the data, which P. Anderson, V. McAlister, A. Sener and P. Luke analyzed. P. Anderson and P. Luke wrote the article, which all authors reviewed and approved for publication.

**References**